A review of anabolic therapies for osteoporosis

Nancy E Lane, Ariella Kelman

Research output: Contribution to journalArticlepeer-review

75 Scopus citations


Osteoporosis results from a loss of bone mass and bone structure such that the bone becomes weak and fractures with very little trauma. Until recently, the approved osteoporosis therapies prevented more bone loss by altering osteoclast activity and lifespan. Recently, attention has turned away from osteoclast inhibition to agents that can stimulate the osteoblast to form new bone, or anabolic agents. This article reviews both approved and experimental anabolic agents that improve bone mass by improving osteoblast activity, or increasing osteoblast number. The use of the anabolic agents to improve bone mass and strength followed by agents that prevent the new bone mass from being lost may offer the ability to cure osteoporosis and reduce bone fracture healing time.

Original languageEnglish (US)
Pages (from-to)214-222
Number of pages9
JournalArthritis Research and Therapy
Issue number5
StatePublished - Oct 2003
Externally publishedYes


  • Anabolic
  • Bone morphogenic protein-2 (BMP-2)
  • Bone morphogenic protein-7
  • Parathyroid hormone hPTH (1-84)
  • Parathyroid hormone rhPTH (1-34)

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'A review of anabolic therapies for osteoporosis'. Together they form a unique fingerprint.

Cite this